Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

TiGenix inks deals with Crohnís disease focus
July 2017
SHARING OPTIONS:

LEUVEN, Belgium—TiGenix announced a number of new partnerships in June centered around Crohn’s disease and ulcerative colitis, including joining the Crohn’s and Colitis Foundation’s President’s Corporate Circle and signing a sponsorship agreement with the European Federation of Crohn’s and Ulcerative Colitis Associations. TiGenix will work with its new partners to expand awareness of complex perianal fistulas in Crohn’s disease. The company is presently advancing a compound, Cx601, for the treatment of complex perianal fistulas.
 
Michael Osso, president and CEO, of the Crohn’s and Colitis Foundation, commented that, “Our President’s Corporate Circle members support us in our mission to do impactful and crucial work to improve the lives of patients living with IBD and find cures for these diseases. We look forward to working with TiGenix alongside our other esteemed and committed industry partners.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.